全文获取类型
收费全文 | 106篇 |
免费 | 10篇 |
专业分类
儿科学 | 15篇 |
基础医学 | 15篇 |
临床医学 | 9篇 |
内科学 | 45篇 |
皮肤病学 | 1篇 |
外科学 | 1篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
药学 | 6篇 |
中国医学 | 2篇 |
肿瘤学 | 20篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 5篇 |
2021年 | 3篇 |
2020年 | 9篇 |
2019年 | 11篇 |
2018年 | 5篇 |
2017年 | 1篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 5篇 |
2013年 | 12篇 |
2012年 | 4篇 |
2011年 | 5篇 |
2010年 | 8篇 |
2009年 | 7篇 |
2008年 | 3篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 3篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
排序方式: 共有116条查询结果,搜索用时 15 毫秒
1.
2.
《Expert opinion on drug safety》2013,12(4):481-489
Background: More than several hundred drugs, toxins, and herbs have been reported to cause blood abnormalities, and drugs account for 20 – 40% of all instances of cytopenias. Objective: In the present paper, we report and discuss the recognition and the management of drug-induced acute neutropenia or agranulocytosis (neutrophil count of < 0.5 × 109/l). Methods: A bibliographic search was performed on the PubMed database of the US National Library of Medicine for articles published from January 1990 to January 2008. Additional not published data of our cohort of drug-induced agranulocytosis in the University Hospital of Strasbourg, France were incorporated in this review. Results/conclusions: Idiosyncratic drug-induced acute neutropenia or agranulocytosis is a serious adverse event due to the frequency of severe infections (such as deep infections, septicemia and septic shock) but modern management with broad spectrum antibiotics and hematopoietic growth factors is likely to improve the prognosis. Given the increased life expectancy, increasing use of medications as a therapeutic modality and subsequent longer exposure to drugs, as well as the development of new agents, healthcare professionals should be aware of this adverse event and its management. 相似文献
3.
Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia 总被引:1,自引:0,他引:1
We describe four patients who developed severe thrombocytopenia which progressed to aplasia after the use of α-interferon in maintenance therapy of chronic phase CML after busulphan induction. On reviewing over 400 patients in the MRC CML III trial we found that there is a risk of cytopenia developing after busulphan therapy and a lesser risk of cytopenias developing after α-interferon therapy. If the therapies are given in a sequential fashion the risk of cytopenia developing appears to be additive, may be pronounced, and may lead to clinically significant problems. Hydroxyurea alone does not lead to sustained cytopenia. Care should be taken to ensure that counts are stable after the use of busulphan before starting α-interferon as maintenance therapy. 相似文献
4.
Jennie E. Murray Louise S. Bicknell Gökhan Yigit Angela L. Duker Margriet van Kogelenberg Sara Haghayegh Dagmar Wieczorek Hülya Kayserili Michael H. Albert Carol A. Wise January Brandon Tjitske Kleefstra Adilia Warris Michiel van der Flier J. Steven Bamforth Kurston Doonanco Lesley Adès Alan Ma Michael Field Diana Johnson Fiona Shackley Helen Firth C. Geoffrey Woods Peter Nürnberg Richard A. Gatti Matthew Hurles Michael B. Bober Bernd Wollnik Andrew P. Jackson 《Human mutation》2014,35(1):76-85
Ligase IV syndrome is a rare differential diagnosis for Nijmegen breakage syndrome owing to a shared predisposition to lympho‐reticular malignancies, significant microcephaly, and radiation hypersensitivity. Only 16 cases with mutations in LIG4 have been described to date with phenotypes varying from malignancy in developmentally normal individuals, to severe combined immunodeficiency and early mortality. Here, we report the identification of biallelic truncating LIG4 mutations in 11 patients with microcephalic primordial dwarfism presenting with restricted prenatal growth and extreme postnatal global growth failure (average OFC ?10.1 s.d., height ?5.1 s.d.). Subsequently, most patients developed thrombocytopenia and leucopenia later in childhood and many were found to have previously unrecognized immunodeficiency following molecular diagnosis. None have yet developed malignancy, though all patients tested had cellular radiosensitivity. A genotype–phenotype correlation was also noted with position of truncating mutations corresponding to disease severity. This work extends the phenotypic spectrum associated with LIG4 mutations, establishing that extreme growth retardation with microcephaly is a common presentation of bilallelic truncating mutations. Such growth failure is therefore sufficient to consider a diagnosis of LIG4 deficiency and early recognition of such cases is important as bone marrow failure, immunodeficiency, and sometimes malignancy are long term sequelae of this disorder. 相似文献
5.
Dang NH Aytac U Sato K O'Brien S Melenhorst J Morimoto C Barrett AJ Molldrem JJ 《British journal of haematology》2003,121(6):857-865
T-large granular lymphocyte lymphoproliferative disorder (T-LGL LPD) is an indolent disease characterized by prolonged cytopenia and the presence of circulating large granular lymphocytes in the patient's peripheral blood. Although the disease is commonly thought of as indolent, most patients eventually require therapy because of recurrent infections secondary to neutropenia as well as a need for frequent blood product transfusions. CD26 is a 110-kDa surface glycoprotein with an essential role in T-cell function, including being a marker of T-cell activation and a mediator of T-cell activating signals. In this study, we evaluated CD26 expression in T-LGL patients and correlate CD26 expression with clinical behaviour. In addition, we examined the potential mechanism of cytopenia that is associated with this disorder. Our findings suggest that CD26 is a marker of aggressive T-LGL LPD and that CD26-related signalling may be aberrant in T-LGL LPD. Furthermore, inhibition of granulocyte-macrophage colony-forming units may be mediated by CD8+ cells of T-LGL LPD patients and is major histocompatibility complex class I-restricted. 相似文献
6.
7.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(9):1753-1768
ObjectiveTo demonstrate experience and feasibility of a precision medicine approach for patients with unexplained cytopenias, defined as low blood counts in one or more cell lineages, persistent for 6 months or longer, in the absence of known nutritional, autoimmune, infectious, toxic, and neoplastic (secondary) causes.Patients and MethodsPatients were evaluated in our clinic between November 8, 2016, and January 12, 2018. After a thorough evaluation of known causes, family history, and appropriate clinical assays, genomic evaluation was performed in a stepwise manner, through Sanger, targeted, and/or whole-exome sequencing. Variants were analyzed and discussed in a genomics tumor board attended by clinicians, bioinformaticians, and molecular biologists.ResultsSixty-eight patients were evaluated in our clinic. After genomic interrogation, they were classified into inherited bone marrow failure syndromes (IBMFS) (n=24, 35%), cytopenias without a known clinical syndrome which included idiopathic and clonal cytopenias of undetermined significance (CCUS) (n=30, 44%), and patients who did not fit into the above two categories (“others,” n=14, 21%). A significant family history was found in only 17 (25%) patients (9 IBMFS, 2 CCUS, and 6 others), whereas gene variants were found in 43 (63%) patients (34 [79%] pathogenic including 12 IBMFS, 17 CCUS, and 5 others]. Genomic assessment resulted in a change in clinical management in 17 (25%) patients, as evidenced by changes in decisions with regards to therapeutic interventions (n=8, 47%), donor choice (n=6, 35%), and/or choice of conditioning regimen for hematopoietic stem cell transplantation (n=8, 47%).ConclusionWe show clinical utility of a real-world algorithmic precision medicine approach for unexplained cytopenias. 相似文献
8.
Baumann I Führer M Behrendt S Campr V Csomor J Furlan I de Haas V Kerndrup G Leguit RJ De Paepe P Noellke P Niemeyer C Schwarz S 《Histopathology》2012,61(1):10-17
Baumann I, Führer M, Behrendt S, Campr V, Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit R J, De Paepe P, Noellke P, Niemeyer C & Schwarz S (2012) Histopathology 61, 10–17 Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria Aims: To evaluate the reproducibility and reliability of the histomorphological criteria differentiating severe aplastic anaemia (SAA) and hypoplastic refractory cytopenia of childhood (RCC), the most frequently acquired hypocellular bone marrow conditions of childhood. Methods and results: We performed a double‐blind interobserver study of 100 different cases of SAA and RCC among seven haematopathologists of the European Working Group of MDS in Childhood (EWOG‐MDS) and the German SAA study. Cases with foci of typical myelodysplastic syndrome (MDS) morphology, such as patchy erythropoiesis with defective maturation, in an otherwise highly hypocellular or adipocytic bone marrow were classified as having RCC. Bone marrow samples without a patchy distribution, few scattered myeloid cells or haematopoietic aplasia were diagnosed as SAA. In only four of 100 cases did the reference pathologists not reach agreement regarding classification as SAA or RCC. The kappa index was 0.79. Conclusions: Our results show that the vast majority of SAA and RCC cases can be reliably differentiated by morphological means alone. A clear differentiation between SAA and RCC at presentation is mandatory for optimizing therapy strategies, and might be responsible for the fact that, in the German childhood SAA study, the probability of developing clonal disease after immunosuppressive therapy has dropped to 3%. 相似文献
9.
Neil Romberg Carole Le Coz Salomé Glauzy Jean-Nicolas Schickel Melissa Trofa Brian E. Nolan Michele Paessler Mina L. Xu Michele P. Lambert Saquib A. Lakhani Mustafa K. Khokha Soma Jyonouchi Jennifer Heimall Patricia Takach Paul J. Maglione Jason Catanzaro F. Ida Hsu Kathleen E. Sullivan Eric Meffre 《The Journal of allergy and clinical immunology》2019,143(1):258-265
10.